The NextSeq 2000 and NextSeq 1000 are both designed to meet growing demand for clinical genomic data at reduced cost, while the collaboration with Roche is focused on advancing clinical diagnostics leveraging Illumina’s pan-cancer assay TruSight Oncology 500.
Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Led by ex-Illumina executives, Element’s founders believe its sequencing technology can reduce costs and inject more competition into a market dominated by their former employer.
The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
Biocept's Target Selector test enables physicians to identify the potential presence of NTRK fusions used to inform on treatment options.
Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
The researchers identified five distinct subtypes of the disease: Basal-like-A, Basal-like-B, Classical-A, Classical-B, and Hybrid, each with unique molecular properties that could be targeted with novel chemotherapy treatments, biologics, and immunotherapies.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Color will help Sanford move its Imagenetics genetic medicine program from an array-based platform to NGS testing, and will expand its partnership with NorthShore University HealthSystem—which has already enrolled 10K patients—to include 30 additional clinics.
Women whose plasma contained circulating tumor DNA had only a 56% chance of being cancer-free two years following chemotherapy and surgery, while those without it had an 81% chance the cancer would not return in the same time span.
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.
Once Genexus is validated, the automated platform could help accelerate access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories.
The deal allows Spanish pharma Almirall to in-license 23andMe's bispecific monoclonal antibody designed to block all three members of the IL-36 cytokine subfamily, which is associated with multiple inflammatory diseases including various dermatological conditions.
GeneDx will develop assays targeting muscular dystrophies, developmental, and reproductive disorders using Saphyr, which detects CNVs, FSHD repeat contractions, repeat expansions, balanced and unbalanced translocations, and other complex rearrangements.
In a UC Davis study, researchers described methods by which someone could learn database genotypes by uploading multiple datasets. For example, a person who uploads approximately 900 genomes could recover at least one allele at SNP sites across up to 82% of the genome of a median person of European ancestries.
Sponsored content brought to you by Cell Therapy Overview CAR-T therapies have quickly shifted the direction of treatments for aggressive diseases, such as blood cancers,...
Breakthrough device designation is designed to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving FDA standards.
For the first time, a deep-learning approach has been used to predict disease-associated metal-relevant site mutations in metalloproteins, providing a new platform to tackle human diseases.
The two companies will look to develop a kitted NGS solution for the identification of biomarkers using blood samples collected from patients enrolled in clinical trials.
More than 67 actionable clinical discoveries were made through deep longitudinal genomic analysis by a group led by Michael Snyder, MD, chair of the...
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine
The multi-year agreement covers co-marketing of future ArcherDX IVD tests used with the Illumina NextSeq 550Dx and MiSeq Dx Systems encompassing oncology testing—including companion diagnostics for therapeutic selection—personalized monitoring, and recurrence surveillance IVD tests.